Brought to you by 
British Biotech licenses ImmunoGen's cancer drug;terminated
20 Aug 2020
Executive Summary
Broadening its cancer platform, British Biotech has licensed exclusive Japanese and European Union rights to ImmunoGen's tumor-activated prodrug, huN901-DM1, for small-cell lung cancer, paying an up-front fee of (uf)$1.5mm, plus royalties on sales in these territories.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com